Yourgene Health PLC Director's dealing (5692Y)

TIDMYGEN

RNS Number : 5692Y

Yourgene Health PLC

09 May 2019

Yourgene Health plc

("Yourgene," the "Company")

Director's dealing

Manchester, UK - 9 May 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it has been notified today that Dr Stephen Little, a director of the Company, has purchased 448,452 ordinary shares of 0.10p each in the Company today at a price of 11.2 pence per ordinary share.

Following the purchase, Dr Stephen Little holds 6,026,736 ordinary shares in the Company representing 1.0% of the Company's issued share capital.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 
For more information, please contact: 
Yourgene Health plc                      Tel: [phone] 
 Lyn Rees, Chief Executive Officer 
 Barry Hextall, Chief Financial Officer 
 Joanne Cross, Head of Marketing 
 [e-mail] 
Cairn Financial Advisers LLP (NOMAD)     Tel: [phone] 
 Liam Murray / James Caithie 
Stifel Nicolaus Europe Limited (Broker)  Tel: [phone] 
 Nicholas Moore / Matthew Balwat / Ben 
 Maddison 
Vigo Communications                      Tel: [phone] 
 Ben Simons / Fiona Henson / Antonia 
 Pollock 
 [e-mail] 
 

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions.

Yourgene Health's first commercialised products are NIPT for Down's Syndrome and other genetic disorders, targeting a share of an emerging billion-dollar global market.

Prenatal screening is an established clinical practice, but accuracy challenges with traditional methods are driving the need for NIPT and other DNA-based reproductive health testing solutions. Our commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Through our technical expertise and partnerships, Yourgene Health is aiming to extend its genetic testing offering into complementary areas of reproductive health and oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

 
 Notification of a Transaction pursuant to Article 19(1) of Regulation 
  (EU) No. 596/2014 
 1       Details of the person discharging managerial responsibilities/person 
          closely associated 
------  -------------------------------------------------------------------------------- 
 a.      Name                                        Dr Stephen Little 
                                                    ------------------------------------ 
 2       Reason for notification 
        ------------------------------------------  ------------------------------------ 
 a.      Position/Status                             Vice Chairman 
        ------------------------------------------  ------------------------------------ 
 b.      Initial notification/                       Initial notification 
          Amendment 
                                                    ------------------------------------ 
 3       Details of the issuer, emission allowance market participant, 
          auction platform, auctioneer or auction monitor 
 a.      Name                                        Yourgene Health plc 
        ------------------------------------------ 
 b.      LEI                                         213800UUIT8BZE7QEH33 
        ------------------------------------------  ------------------------------------ 
 4       Details of the transaction(s): section to be repeated for 
          (i) each type of instrument; (ii) each type of transaction; 
          (iii) each date; and (iv) each place where transactions have 
          been conducted 
------  -------------------------------------------------------------------------------- 
 a.      Description of                              Ordinary shares of 0.10p each 
          the financial 
          instrument, type                            ISIN: GB00BN31ZD89 
          of instrument 
 
          Identification 
          Code 
        ------------------------------------------  ------------------------------------ 
 b.      Nature of the                               Purchase of ordinary shares 
          transaction 
        ------------------------------------------  ------------------------------------ 
 
 c.      Price(s) and volume(s)                       Price(s)         Volume(s) 
        ------------------------------------------   --------------- 
                                                      11.2p            448,452 
                                                     ---------------  --------------- 
 
 e.      Date of the transaction                     9 May 2019 
        ------------------------------------------  ------------------------------------ 
 f.      Place of the transaction                    London Stock Exchange 
        ------------------------------------------  ------------------------------------ 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHEASSNEESNEFF

(END) Dow Jones Newswires

May 09, 2019 11:07 ET (15:07 GMT)